Invivyd FY revenue rises; operating expenses cut sharply

Invivyd

05/03/2026 12:17

Overview

Biopharmaceutical company reported Q4 PEMGARDA net product revenue up 25% yr/yr

Loss per share for 2025 beat analyst expectations

Net loss for 2025 beat analyst estimates

Outlook

Invivyd expects top-line data from DECLARATION trial mid-2026

Company anticipates advancing RSV candidate VBY329 toward IND readiness in 2H 2026

Invivyd's cash reserves are expected to support DECLARATION trial and pipeline programs

Result Drivers

PEMGARDA REVENUE GROWTH - Q4 PEMGARDA revenue increased 25% yr/yr and 31% qtr/qtr, driven by commercial execution and appeal for monoclonal antibody prophylaxis

OPERATING EXPENSES REDUCED - Operating expenses were reduced by nearly half, demonstrating financial discipline

Company press release: ID:nGNX8b1R3F

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
$53.43 mln
FY EPS
Beat
-$0.30
-$0.39 (4 Analysts)
FY Net Income
Beat
-$52.49 mln
-$57.82 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Invivyd Inc is $10.00, about 484.8% above its March 4 closing price of $1.71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)